Gilead hep-C drug passes test

Investor's Business Daily

The biotech drugmaker said a third-stage test of its hepatitis C drug sofosbuvir met expectations, with 78% of participating patients showing no signs of the disease 3 months after completing treatment. Gilead Science (GILD) also said the European Commission approved two new indications for its drug Viread: to treat HIV-1infection in children and adolescents, and for chronic hepatitis B in adolescents. Shares fell 1%

Rates

View Comments (0)